Actinium Pharmaceuticals Inc (ATNM):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Actinium Pharmaceuticals Inc (ATNM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C7943)・商品コード:DATA904C7943
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:53
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Actinium Pharmaceuticals Inc (ATNM), formerly Cactus Ventures Inc is a biopharmaceutical company that provides development of cancer immunotherapies. The company provides pipeline products such as Iomab-B that is used for hematopoietic stem cells transplantation. It provides Iomab-B through the monoclonal antibody BC8 that targets CD45, an antigen expressed on leukemia and lymphoma cancer cells, B cells and stem cells. ATNM provides mab expension and biobetters development in stratergical platform. It offers other pipeline products such as actimab-A for treatment of acute myeloid leukemia; actimab-C for colon cancer and actimab-P for the treatment of prostate cancer. The company uses alpha particle immunotherapy platform technology for drug development. ATNM is headquartered in New York, the US.

Actinium Pharmaceuticals Inc (ATNM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Actinium Pharma Raises US$5 Million In First Closing Of Venture Financing Round 11
Partnerships 12
Actinium Pharma Enters into Research and Option Agreement with Astellas Pharma 12
Actinium Pharma Partners with Vector Oncology 13
Actinium Pharma Enters into Agreement with Medpace 14
Actinium Pharma Enters into Co-Development Agreement with Albert Einstein College of Medicine 15
Licensing Agreements 16
Actinium Pharma Enters Into Licensing Agreement With Fred Hutchinson Cancer Research Center For BC8 16
Equity Offering 18
Actinium Pharma Prices Rights Offering of Units for USD25 Million 18
Actinium Pharma Raises USD16.1 Million in Public Offering of Shares and Warrants 20
Actinium Pharma Raises USD10 Million in Public Offering of Shares 22
Actinium Pharma Raises USD5 Million in Private Placement of Shares 24
Actinium Pharma Raises USD20 Million in Public Offering of Shares and warrants 26
Actinium Pharma Raises USD13.7 Million in Public Offering of Shares 28
Actinium Pharma Completes Second Tranche Of Private Placement Of Securities For US$3.3 Million 30
Actinium Pharma Completes Private Placement Of Shares For US$3.5 Million Upon Exercise Of Warrants 31
Actinium Pharma Plans IPO 32
Acquisition 33
Cactus Ventures Completes Acquisition Of Actinium Pharma In Reverse Takeover Transaction 33
Actinium Pharmaceuticals Inc – Key Competitors 34
Actinium Pharmaceuticals Inc – Key Employees 35
Actinium Pharmaceuticals Inc – Locations And Subsidiaries 36
Head Office 36
Recent Developments 37
Corporate Communications 37
May 01, 2018: Actinium Pharmaceuticals Appoints Dr. Jeffrey Chell, Bone Marrow Transplant Visionary and Chief Executive Officer Emeritus of Be The Match and National Marrow Donor Program, to its Board of Directors 37
Feb 08, 2018: Actinium Appoints Anil Kapur as Chief Commercial Officer to Build Critical Commercial & Launch Capabilities Focused on Myeloablation 38
Jan 08, 2018: Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on the Company’s AWE Technology Platform and Research Programs 39
Jun 09, 2017: Actinium Pharmaceuticals Announces Appointment of Sandesh Seth as Chief Executive Officer 40
Mar 28, 2017: Actinium Pharmaceuticals Appoints Pharmaceutical Industry Executive Ajit S. Shetty, Ph.D., to the Company’s Board of Directors 41
Jan 18, 2017: Actinium Strengthens Executive Team and Enhances Clinical Development Capabilities with the Appointment of Dr. Mark Berger as Chief Medical Officer 42
Product News 44
12/11/2017: Actinium Pharmaceuticals Highlights Data at the American Society of Hematology Annual Meeting Showing CD33 Expression in a Significant Number of Multiple Myeloma Patients Supporting the Rationale for Actimab-M 44
Nov 14, 2017: Actinium Pharmaceuticals Launches the AWE Program aka Actinium Warhead Enabling Program to Enable Collaborations Based on Its Actinium-225 Technology Platform 45
Oct 01, 2018: Actinium launches Iomab-ACT program offering its targeted chemo-free lymphodepletion technology as a universal solution to CAR-T product developers 47
Clinical Trials 48
Sep 13, 2017: Actinium Pharmaceuticals Highlights on Actimab-M at the Society of Hematologic Oncology 2017 Annual Meeting 48
Feb 13, 2017: Actinium Pharmaceuticals’ Company Presentation at BIO CEO & Investor Conference to Provide Highlights of Recently Announced Actimab-M Trial in Multiple Myeloma 49
Feb 07, 2017: Actinium Pharmaceuticals Announces Pipeline Expansion with Initiation of Clinical Trial of Actimab-M in Multiple Myeloma 50
Other Significant Developments 51
Jan 25, 2018: Actinium Pharmaceuticals Issues Letter to Investors Providing Company Update and Outlook for 2018 51
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Actinium Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Actinium Pharma Raises US$5 Million In First Closing Of Venture Financing Round 11
Actinium Pharma Enters into Research and Option Agreement with Astellas Pharma 12
Actinium Pharma Partners with Vector Oncology 13
Actinium Pharma Enters into Agreement with Medpace 14
Actinium Pharma Enters into Co-Development Agreement with Albert Einstein College of Medicine 15
Actinium Pharma Enters Into Licensing Agreement With Fred Hutchinson Cancer Research Center For BC8 16
Actinium Pharma Prices Rights Offering of Units for USD25 Million 18
Actinium Pharma Raises USD16.1 Million in Public Offering of Shares and Warrants 20
Actinium Pharma Raises USD10 Million in Public Offering of Shares 22
Actinium Pharma Raises USD5 Million in Private Placement of Shares 24
Actinium Pharma Raises USD20 Million in Public Offering of Shares and warrants 26
Actinium Pharma Raises USD13.7 Million in Public Offering of Shares 28
Actinium Pharma Completes Second Tranche Of Private Placement Of Securities For US$3.3 Million 30
Actinium Pharma Completes Private Placement Of Shares For US$3.5 Million Upon Exercise Of Warrants 31
Actinium Pharma Plans IPO 32
Cactus Ventures Completes Acquisition Of Actinium Pharma In Reverse Takeover Transaction 33
Actinium Pharmaceuticals Inc, Key Competitors 34
Actinium Pharmaceuticals Inc, Key Employees 35

List of Figures
Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Actinium Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★調査レポート[Actinium Pharmaceuticals Inc (ATNM):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C7943)販売に関する免責事項を必ずご確認ください。
★調査レポート[Actinium Pharmaceuticals Inc (ATNM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆